

ASX ANNOUNCEMENT

BENITEC CEO DISCUSSES ARROWHEAD'S HEPATITIS B RESULTS

Sydney, Australia - October 1, 2015: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to invite investors to listen to an audio interview of Managing Director and CEO, Dr Peter French discuss Arrowhead's recent clinical trial results of their siRNA-based hepatitis B therapeutic and why this is supportive of Benitec's ddRNAi-based approach for hepatitis B.

To listen to the audio, please copy the following link into your browser:

<http://www.brrmedia.com/event/140412>

This announcement has been prepared for publication in Australia and may not be released in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.